Orphazyme A/S
Investor news                                                                                                                                                        
No. 13/2018                                                                                                                                                         
Company Registration No. 32266355

Copenhagen, November 20, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Redeye Life Science Day in Stockholm, Sweden, on November 21, 2018.

For additional information, please contact

Orphazyme A/S
Anders Hinsby, CEO                             +45 31 44 31 39

About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.  

Attachment

• 13-2018 Orphazyme to present at Redeye Life Science Day